• Explore /
  • Poster
  • / Study of cabozantinib in second line under real-life setting in patients with advanced renal cell carcinoma (aRCC): Study design of a French retrospective, multicenter study (OCTOPUS).

Study of cabozantinib in second line under real-life setting in patients with advanced renal cell carcinoma (aRCC): Study design of a French retrospective, multicenter study (OCTOPUS).

Abstract Poster

Authors

null

Antoine Thiery-Vuillemin

CHRU Besançon-Hôpital J.Minjoz, Besançon, France

Antoine Thiery-Vuillemin , Loic Mourey , David Pasquier , Constance Thibault , Jean-Christophe Bernhard , Laetitia Zara , Valérie Perrot , Laurence Albiges

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05444933

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr TPS744)

DOI

10.1200/JCO.2023.41.6_suppl.TPS744

Abstract #

TPS744

Poster Bd #

N2

Abstract Disclosures

Similar Posters

First Author: Michael D. Staehler

First Author: Frede Donskov

First Author: Constance Thibault

First Author: Michael D. Staehler